These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 12417739)

  • 1. Short constrained peptides that inhibit HIV-1 entry.
    Sia SK; Carr PA; Cochran AG; Malashkevich VN; Kim PS
    Proc Natl Acad Sci U S A; 2002 Nov; 99(23):14664-9. PubMed ID: 12417739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region.
    Eckert DM; Kim PS
    Proc Natl Acad Sci U S A; 2001 Sep; 98(20):11187-92. PubMed ID: 11572974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Covalent stabilization of coiled coils of the HIV gp41 N region yields extremely potent and broad inhibitors of viral infection.
    Bianchi E; Finotto M; Ingallinella P; Hrin R; Carella AV; Hou XS; Schleif WA; Miller MD; Geleziunas R; Pessi A
    Proc Natl Acad Sci U S A; 2005 Sep; 102(36):12903-8. PubMed ID: 16129831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of HIV entry inhibitors targeted to the coiled-coil regions of gp41.
    Jiang S; Debnath AK
    Biochem Biophys Res Commun; 2000 Mar; 269(3):641-6. PubMed ID: 10720469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target.
    Chan DC; Chutkowski CT; Kim PS
    Proc Natl Acad Sci U S A; 1998 Dec; 95(26):15613-7. PubMed ID: 9861018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thermodynamics of peptide inhibitor binding to HIV-1 gp41.
    Cole JL; Garsky VM
    Biochemistry; 2001 May; 40(19):5633-41. PubMed ID: 11341828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of HIV type 1 infectivity by constrained alpha-helical peptides: implications for the viral fusion mechanism.
    Judice JK; Tom JY; Huang W; Wrin T; Vennari J; Petropoulos CJ; McDowell RS
    Proc Natl Acad Sci U S A; 1997 Dec; 94(25):13426-30. PubMed ID: 9391041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein design of a bacterially expressed HIV-1 gp41 fusion inhibitor.
    Deng Y; Zheng Q; Ketas TJ; Moore JP; Lu M
    Biochemistry; 2007 Apr; 46(14):4360-9. PubMed ID: 17371053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A salt bridge between an N-terminal coiled coil of gp41 and an antiviral agent targeted to the gp41 core is important for anti-HIV-1 activity.
    Jiang S; Debnath AK
    Biochem Biophys Res Commun; 2000 Apr; 270(1):153-7. PubMed ID: 10733920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydrophobic mutations in buried polar residues enhance HIV-1 gp41 N-terminal heptad repeat-C-terminal heptad repeat interactions and C-peptides' anti-HIV activity.
    Zheng B; Wang K; Lu L; Yu F; Cheng M; Jiang S; Liu K; Cai L
    AIDS; 2014 Jun; 28(9):1251-60. PubMed ID: 24625369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential inhibition of HIV-1 and SIV envelope-mediated cell fusion by C34 peptides derived from the C-terminal heptad repeat of gp41 from diverse strains of HIV-1, HIV-2, and SIV.
    Gustchina E; Hummer G; Bewley CA; Clore GM
    J Med Chem; 2005 Apr; 48(8):3036-44. PubMed ID: 15828842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design of a peptide inhibitor that blocks the cell fusion mediated by glycoprotein 41 of human immunodeficiency virus type 1.
    Jin BS; Ryu JR; Ahn K; Yu YG
    AIDS Res Hum Retroviruses; 2000 Nov; 16(17):1797-804. PubMed ID: 11118065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of HIV-1 entry before gp41 folds into its fusion-active conformation.
    Kliger Y; Shai Y
    J Mol Biol; 2000 Jan; 295(2):163-8. PubMed ID: 10623516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-activity relationships of anti-HIV-1 peptides with disulfide linkage between D- and L-cysteine at positions i and i+3, respectively, derived from HIV-1 gp41 C-peptide.
    Lee MK; Kim HK; Lee TY; Hahm KS; Kim KL
    Exp Mol Med; 2006 Feb; 38(1):18-26. PubMed ID: 16520549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Electrostatically constrained alpha-helical peptide inhibits replication of HIV-1 resistant to enfuvirtide.
    Nishikawa H; Nakamura S; Kodama E; Ito S; Kajiwara K; Izumi K; Sakagami Y; Oishi S; Ohkubo T; Kobayashi Y; Otaka A; Fujii N; Matsuoka M
    Int J Biochem Cell Biol; 2009 Apr; 41(4):891-9. PubMed ID: 18834950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-peptide fusion inhibitors with high potency against wild-type and enfuvirtide-resistant HIV-1.
    Chong H; Yao X; Qiu Z; Sun J; Zhang M; Waltersperger S; Wang M; Liu SL; Cui S; He Y
    FASEB J; 2013 Mar; 27(3):1203-13. PubMed ID: 23233535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The hydrophobic pocket contributes to the structural stability of the N-terminal coiled coil of HIV gp41 but is not required for six-helix bundle formation.
    Dwyer JJ; Hasan A; Wilson KL; White JM; Matthews TJ; Delmedico MK
    Biochemistry; 2003 May; 42(17):4945-53. PubMed ID: 12718536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 membrane fusion mechanism: structural studies of the interactions between biologically-active peptides from gp41.
    Lawless MK; Barney S; Guthrie KI; Bucy TB; Petteway SR; Merutka G
    Biochemistry; 1996 Oct; 35(42):13697-708. PubMed ID: 8885850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extremely Thermostabilizing Core Mutations in Coiled-Coil Mimetic Proteins of HIV-1 gp41 Produce Diverse Effects on Target Binding but Do Not Affect Their Inhibitory Activity.
    Cano-Muñoz M; Cesaro S; Morel B; Lucas J; Moog C; Conejero-Lara F
    Biomolecules; 2021 Apr; 11(4):. PubMed ID: 33921495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multi-functional peptide as an HIV-1 entry inhibitor based on self-concentration, recognition, and covalent attachment.
    Zhao L; Tong P; Chen YX; Hu ZW; Wang K; Zhang YN; Zhao DS; Cai LF; Liu KL; Zhao YF; Li YM
    Org Biomol Chem; 2012 Aug; 10(32):6512-20. PubMed ID: 22760295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.